Literature DB >> 12015471

PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy.

Michael H Gollob1, Martin S Green, Anthony S L Tang, Robert Roberts.   

Abstract

Genetic studies of families with inherited cardiac rhythm disturbances have established a molecular basis for ventricular arrhythmogenic disorders. Genes responsible for the long QT syndrome, Brugada syndrome, and polymorphic ventricular tachycardia have been identified. The elucidation of genetic defects responsible for more commonly occurring supraventricular rhythm disturbances have not been as forthcoming, with the exception of SCN5A mutations known to cause conduction system disease. Recently, we identified the genetic cause of a familial arrhythmogenic syndrome characterized by ventricular preexcitation and tachyarrhythmias (Wolff-Parkinson-White syndrome), progressive conduction system disease, and cardiac hypertrophy. The causative gene was shown to be the gamma-2 regulatory subunit (PRKAG2) of AMP-activated protein kinase. The role of AMP-activated protein kinase in the regulation of the glucose metabolic pathway in muscle suggests that genetic defects in PRKAG2 may induce a previously undescribed cardiac glycogenosis syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12015471     DOI: 10.1097/00001573-200205000-00004

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  26 in total

Review 1.  CK flux or direct ATP transfer: versatility of energy transfer pathways evidenced by NMR in the perfused heart.

Authors:  F Joubert; P Mateo; B Gillet; J C Beloeil; J L Mazet; J A Hoerter
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

Review 2.  Clinical Spectrum of PRKAG2 Syndrome.

Authors:  Andrea Giuseppe Porto; Francesca Brun; Giovanni Maria Severini; Pasquale Losurdo; Enrico Fabris; Matthew R G Taylor; Luisa Mestroni; Gianfranco Sinagra
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-01

3.  PRKAG2 mutations presenting in infancy.

Authors:  Rachel D Torok; Stephanie L Austin; Chanika Phornphutkul; Kathleen M Rotondo; Deeksha Bali; Gregory H Tatum; Stephanie B Wechsler; Anne F Buckley; Priya S Kishnani
Journal:  J Inherit Metab Dis       Date:  2017-08-11       Impact factor: 4.982

Review 4.  AMP-activated protein kinase, stress responses and cardiovascular diseases.

Authors:  Shaobin Wang; Ping Song; Ming-Hui Zou
Journal:  Clin Sci (Lond)       Date:  2012-06       Impact factor: 6.124

5.  Crystallization of the glycogen-binding domain of the AMP-activated protein kinase beta subunit and preliminary X-ray analysis.

Authors:  Galina Polekhina; Susanne C Feil; Abhilasha Gupta; Paul O'Donnell; David Stapleton; Michael W Parker
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2004-10-09

6.  Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency.

Authors:  Barbara Burwinkel; John W Scott; Christoph Bührer; Frank K H van Landeghem; Gerald F Cox; Callum J Wilson; D Grahame Hardie; Manfred W Kilimann
Journal:  Am J Hum Genet       Date:  2005-05-02       Impact factor: 11.025

7.  Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.

Authors:  Chang Xie; Ya-Ping Zhang; Lu Song; Jie Luo; Wei Qi; Jialu Hu; Danbo Lu; Zhen Yang; Jian Zhang; Jian Xiao; Bin Zhou; Jiu-Lin Du; Naihe Jing; Yong Liu; Yan Wang; Bo-Liang Li; Bao-Liang Song; Yan Yan
Journal:  Cell Res       Date:  2016-08-30       Impact factor: 25.617

Review 8.  Bateman domains and adenosine derivatives form a binding contract.

Authors:  Bruce E Kemp
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 9.  Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases.

Authors:  Adam Mohmand-Borkowski; W H Wilson Tang
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

10.  Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site.

Authors:  Julian Adams; Zhi-Ping Chen; Bryce J W Van Denderen; Craig J Morton; Michael W Parker; Lee A Witters; David Stapleton; Bruce E Kemp
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.